Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardonilizumab + nab-paclitaxel + cisplatin neoadjuvant therapy for locally advanced cervical cancer
ChiCTR2400094554Phase 2Recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Jun 2024
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab, paclitaxel and cisplatin in Cervical Cancer (CC), sponsored by Peking University Third Hospital. Primary endpoint: Pathological complete response rate. Started Jun 2024; status: recruiting.
02
Drugs
cadonilimabpaclitaxelcisplatin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2400094554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094554.